Xponance Inc. Acquires 3,851 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Xponance Inc. lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 20.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,524 shares of the company’s stock after acquiring an additional 3,851 shares during the period. Xponance Inc.’s holdings in Elanco Animal Health were worth $273,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ELAN. Steward Partners Investment Advisory LLC increased its holdings in Elanco Animal Health by 28.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock worth $124,000 after purchasing an additional 2,264 shares in the last quarter. DDD Partners LLC bought a new stake in Elanco Animal Health during the fourth quarter worth $5,974,000. Geode Capital Management LLC raised its position in Elanco Animal Health by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after buying an additional 65,303 shares during the last quarter. Atom Investors LP lifted its stake in Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock valued at $5,081,000 after acquiring an additional 261,559 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after acquiring an additional 209,734 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 2.4 %

Shares of NYSE ELAN opened at $10.81 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market capitalization of $5.34 billion, a PE ratio of 27.01, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80. The business’s fifty day moving average price is $11.27 and its 200-day moving average price is $12.48.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.08 earnings per share. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.57% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.